MYNDF.US MYND Lifesciencs Inc
- Market cap
- USD 387K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2024.
Is MYNDF.US undervalued?
Graham numberThe Graham number of MYND Lifesciencs Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MYND Lifesciencs Inc fundamental analysis
No fundamental analysis for MYND Lifesciencs Inc yet.
MYND Lifesciencs Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MYND Lifesciencs Inc
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
Full company profileMYND Lifesciencs Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
MYND Lifesciencs Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | - | 0.00 | 0.00 | 93.0K | 1.33 |
| Gross Profit | - | - | -69.5K | -180K | -240K | -279K |
| Operating Income | -2.54K | -56.5K | -4.29M | -3.00M | -1.83M | -1.20M |
| EBITDA | 2.54K | - | -4.21M | -3.00M | -1.81M | -1.19M |
| Net Income | -2.54K | -56.5K | -4.37M | -3.57M | -1.52M | -1.35M |
| EPS | 0.00 | 0.00 | -0.10 | -0.08 | -0.03 | -0.03 |
| Balance Sheet | ||||||
| Total Assets | - | 70.00 | 2.67M | 654K | 798K | 720K |
| Total Liabilities | 1.83K | 53.7K | 2.74M | 4.19M | 5.77M | 6.71M |
| Shareholders' Equity | -1.83K | -53.6K | -68.0K | -3.53M | -4.98M | -5.99M |
| Cash & Short-term Investments | - | - | 1.90M | 412.00 | 257.00 | 497.00 |
| Total Debt | - | - | 2.32M | 2.59M | 3.00M | 3.00M |
| Cash Flow | ||||||
| Operating Cash Flow | -708.00 | -2.78K | -2.98M | -1.82M | -198K | 321.33 |
| Capital Expenditure | 43.9K | 43.9K | 149K | 0.00 | 0.00 | 3.48K |
| Free Cash Flow | -708.00 | -2.78K | -3.13M | -1.82M | -198K | -1.42K |
| Ratios | ||||||
| ROA | - | -80,665.7% | -163.5% | -545.4% | -190.3% | -187.4% |
| Net Profit Margin | - | - | - | - | -1,632.3% | -101,413,734.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MYND Lifesciencs Inc dividends
MYND Lifesciencs Inc has not paid dividends in the last 5 fiscal years.
Who owns MYND Lifesciencs Inc
- Insiders 59.83%
- Institutions 0.00%
- Public & others 40.17%
- Shares outstanding 47.8M
- Free float 33.2M
MYND Lifesciencs Inc company profile
- Company name
- MYND Lifesciencs Inc
- Ticker
- MYNDF.US
- ISIN
- CA62857B1094
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- Unit 150, Port Coquitlam, BC, Canada, V3C 2B2
- Phone
- 403 559 6779
- Website
- myndsciences.com
About MYND Lifesciencs Inc
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
MYND Lifesciencs Inc management
4- Dr. Wilfred A. JefferiesCo-Founder & Chief Science Officer · born 1958
- Mr. Lih-Ming TamCFO & Senior Controller
- Dr. Chaahat S.B SinghSenior Operations & Research Manager
- Dr. Iryna Saranchova M.D., Ph.D.Chief Clinical Officer